PEGYLATED INTERFERON +/- RIBAVIRIN FOR CHILDREN WITH HCV

聚乙二醇化干扰素/利巴韦林治疗丙型肝炎儿童

• 批准号: 7607259
• 负责人: MAUREEN M JONAS
• 金额: $ 1.59万
• 依托单位: BOSTON CHILDREN'S HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607259
• 关键词: Behavior; Body Composition; Body mass index; Child; Chronic; Cognitive; Computer Retrieval of Information on Scientific Projects Database; Development; Funding; Goals; Grant; Growth; Hepatitis C; Hepatitis C virus; Institution; Interferons; Outcome; Quality of life; Rate; Research; Research Personnel; Resources; Ribavirin; Safety; Source; United States National Institutes of Health; peginterferon alfa-2a; psychologic; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The over-all goals of this study are: 1) To assess the safety and efficacy of peginterferon alfa-2a (PEG-2a) in combination with ribavirin (RV) and PEG-2a alone for the treatment of chronic hepatitis C virus (CHC) infection in children. 2) To determine whether PEG-2a in combination with RV or PEG-2a alone will result in a higher sustained virologic response rate in children with CHC. 3) To examine the effects of PEG-2a (with or without concomitant RV) treatment on body mass index, body composition, and linear growth in children infected with hepatitis C. 4) To characterize short- and long-term outcomes, including health-related QOL, cognitive and developmental and psychological functioning and behavior in children treated with PEG-2a (with or without concomitant RV).

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的总体目的是：1）评价聚乙二醇干扰素α-2a（PEG-2a）联合利巴韦林（RV）与单用PEG-2a治疗儿童慢性丙型肝炎病毒（CHC）感染的安全性和有效性。 2)确定PEG-2a联合RV或PEG-2a单药治疗CHC儿童是否会导致更高的持续病毒学应答率。 3)检查PEG-2a（伴或不伴RV）治疗对丙型肝炎感染儿童的体重指数、身体组成和线性生长的影响。 4)描述接受PEG-2a治疗（伴或不伴RV）的儿童的短期和长期结局，包括健康相关QOL、认知和发育以及心理功能和行为。